[{"id":"decd78ad-47c4-46e7-8ee3-7f5cb5f5bf54","acronym":"","url":"https://clinicaltrials.gov/study/NCT05759793","created_at":"2023-03-08T17:01:40.860Z","updated_at":"2024-07-02T16:35:31.991Z","phase":"Phase 1","brief_title":"A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia","source_id_and_acronym":"NCT05759793","lead_sponsor":"Nanjing IASO Biotechnology Co., Ltd.","biomarkers":" IL6 • GPRC5D","pipe":" | ","alterations":" GPRC5D expression","tags":["IL6 • GPRC5D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPRC5D expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RD118"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 03/30/2023","start_date":" 03/30/2023","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-10-24"},{"id":"97c93ca1-310a-41c9-b2fa-260a0df225ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT05219721","created_at":"2022-02-05T18:28:42.329Z","updated_at":"2024-07-02T16:36:09.970Z","phase":"Phase 1","brief_title":"A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia","source_id_and_acronym":"NCT05219721","lead_sponsor":"Chunrui Li","biomarkers":" IL6 • GPRC5D","pipe":" | ","alterations":" GPRC5D expression","tags":["IL6 • GPRC5D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPRC5D expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RD118"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 03/17/2022","start_date":" 03/17/2022","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2022-05-24"}]